

HONG KONG PUBLIC OFFERING – WHITE FORM eIPO SERVICE PROVIDER APPLICATION FORM 香港公開發售 – 白表eIPO服務供應商申請表格
Please use this Application Form if you are a White Form eIPO Service Provider and are applying for Hong Kong Offer Shares on behalf of underlying applicants.
倘閣下為白表eIPO服務供應商，並代表相關申請人申請認購香港發售股份，請使用本申請表格。



開拓藥業有限公司*
KINTOR PHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering : 92,347,500 Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares : 9,235,000 Shares (subject to adjustment)
Number of International Offer Shares : 83,112,500 Shares (subject to adjustment and the Over-allotment Option)
Maximum Offer Price : HK\$20.15 per Offer Share plus brokerage of 1.0%,
SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%
(payable in full on application in Hong Kong dollars and subject to refund)
Stock code : 9939

全球發售

全球發售項下的發售股份數目 : 92,347,500 股股份 (視乎超額配股權行使與否而定)
香港發售股份數目 : 9,235,000 股股份 (可予調整)
國際發售股份數目 : 83,112,500 股股份 (可予調整及視乎超額配股權行使與否而定)
最高發售價 : 每股發售股份20.15 港元，另加1.0% 經紀佣金、0.0027% 證監會交易費及0.005% 聯交所交易費 (須於申請時以港元繳足，多繳股款可予退還)
股份代號 : 9939

Please read carefully the prospectus of Kintor Pharmaceutical Limited (the "Company") dated 12 May 2020 (the "Prospectus") (in particular, the section "How to Apply for Hong Kong Offer Shares" in the Prospectus) and the guidelines on the back of this Application Form before completing this Application Form. Terms used in this Application Form shall have the same meanings as those defined in the Prospectus unless defined herein.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and Hong Kong Securities Clearing Company Limited ("HKSCC") take no responsibility for the contents of this Application Form, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of this Application Form.

A copy of this Application Form, together with a copy of each of the WHITE and YELLOW Application Forms, the Prospectus and the other documents specified in Appendix VI headed "Documents Delivered to the Registrar of Companies in Hong Kong and Available for Inspection" to the Prospectus have been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), The Securities and Futures Commission (the "SFC") and the Registrar of Companies in Hong Kong take no responsibility as to the contents of any of these documents.

Your attention is drawn to the paragraph headed "Personal Information Collection Statement" which sets out the policies and practices of the Company and its Hong Kong Share Registrar in relation to personal data and compliance with the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong).

Nothing in this Application Form or the Prospectus constitutes an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Hong Kong Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This Application Form and the Prospectus are not for distribution, directly or indirectly, in or into the United States, nor is this application an offer of Shares for sale in the United States. The Hong Kong Offer Shares have not been and will not be registered under the U.S. Securities Act or any state securities law in the United States and may not be offered, sold, pledged or transferred within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. The Hong Kong Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of each jurisdiction where those offers and sales occur. No public offering of the Hong Kong Offer Shares will be made in the United States.

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction. This Application Form and the Prospectus are addressed to you personally. Any forwarding or distribution or reproduction of this Application Form or the Prospectus in whole or in part is unauthorised. Failure to comply with this directive may result in a violation of the U.S. Securities Act or the applicable laws of other jurisdictions.

Allocation of Offer Shares

The allocation of Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the "Structure of the Global Offering – The Hong Kong Public Offering – Reallocation" in the Prospectus. In particular, the Joint Global Coordinators may reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering, provided that the total number of the Offer Shares available under the Hong Kong Public Offering shall not be increased to more than 18,470,000 Offer Shares, representing two times the number of Offer Shares initially available for subscription under the Hong Kong Public Offering and 20% of the total number of the Offer Shares initially available for subscription under the Global Offering, and the final Offer Price shall be fixed at the bottom end of the Offer Price Range (i.e. HK\$17.80 per Offer Share) stated in the Prospectus in accordance with the Guidance Letter HKEX-GL91-18 issued by the Stock Exchange.

To: Kintor Pharmaceutical Limited
The Sole Sponsor
The Joint Global Coordinators
The Hong Kong Underwriters

在填寫本申請表格前，請細閱Kintor Pharmaceutical Limited (本公司)日期為2020年5月12日的招股章程(招股章程)，尤其是招股章程「如何申請香港發售股份」一節，及本申請表格背面的指引。除非另有界定，否則本申請表格所用詞語與招股章程所界定者具相同涵義。

香港交易及結算所有限公司、香港聯合交易所有限公司(聯交所)及香港中央結算有限公司(香港結算)對本申請表格的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本申請表格全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。

本申請表格連同白色及黃色申請表格、招股章程及招股章程附錄六「送呈香港公司註冊處處長及備查文件」所列的其他文件，已遵照香港法例第32章公司(清盤及雜項條文)條例第342C條之規定，送呈香港公司註冊處處長登記。證券及期貨事務監察委員會(證監會)及香港公司註冊處處長對該等文件的任何內容概不負責。

閣下請留意「個人資料收集聲明」一段，當中載有本公司及其香港證券登記處有關個人資料及遵守香港法例第486章《個人資料(私隱)條例》的政策及常規。

本申請表格或招股章程所載者概不構成出售要約或要約購買的游說，而在任何作出有關要約、游說或出售即屬違法的司法管轄區內，概不得出售任何香港發售股份。本申請表格及招股章程不得在美國境內直接或間接派發，而此項申請亦不得在美國境內發售的要約。香港發售股份未曾亦不會根據美國證券法或美國任何州證券法登記，且不得在美國境內發售、出售、抵押或轉讓，惟根據美國證券法及適用美國州證券法獲豁免登記規定或並非受該等登記規定規限的交易除外。香港發售股份依據美國證券法S規例以及進行發售及出售的各司法管轄區適用法例於離岸交易中在美國境外提呈發售及出售。將不會於美國進行香港發售股份的公開發售。

在任何根據有關司法管轄區法律不得發送、派發或複製本申請表格及招股章程之司法管轄區內，本申請表格及招股章程概不得以何種方式發送或派發或複製(全部或部分)。本申請表格及招股章程僅予閣下本人。概不得發送或派發或複製本申請表格或招股章程的全部或部分。如未能遵守此項指令，可能違反美國證券法或其他司法管轄區的適用法律。

分配發售股份

香港公開發售與國際發售之間的發售股份分配將按招股章程「全球發售的架構 – 香港公開發售 – 重新分配」所述者重新分配。具體而言，聯席全球協調人或會將發售股份從國際發售重新分配至香港公開發售，以滿足香港公開發售的有效申請，惟根據聯交所發售的指引HKEX-GL91-18，根據香港公開發售可供認購的發售股份總數不得增加至超過18,470,000股發售股份，相當於根據香港公開發售初步可供認購發售股份數目的兩倍及根據全球發售初步可供認購發售股份總數20%，而且最終發售價須定為招股章程所述發售價範圍的下限(即每股發售股份17.80港元)。

致: Kintor Pharmaceutical Limited
獨家保薦人
聯席全球協調人
香港包銷商

We confirm that we have (i) complied with the Guidelines for Electronic Public Offerings and the Operational Procedures for White Form eIPO Applications submitted via banks/stockbrokers and all applicable laws and regulations (whether statutory or otherwise) in relation to the provision of our White Form eIPO services in connection with the Hong Kong Public Offering; and (ii) read the terms and conditions and application procedures set out in the Prospectus and this Application Form and agree to be bound by them. Applying on behalf of each of the underlying applicants to whom this application relates, we:

- apply for the number of Hong Kong Offer Shares set out below, on the terms and conditions of the Prospectus and this Application Form, and subject to the Memorandum and the Articles of Association;
- enclose payment in full for the Hong Kong Offer Shares applied for, including brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%;
- confirm that the underlying applicants have undertaken and agreed to accept the Hong Kong Offer Shares applied for, or any lesser number allocated to such underlying applicants on this application;
- declare that this is the only application made and the only application intended by the underlying applicant(s) to be made whether on a WHITE or YELLOW Application Form, or by giving electronic application instructions to HKSCC or through the designated White Form eIPO Service Provider under the White Form eIPO service (www.eipo.com.hk), to benefit the underlying applicant(s) or the person for whose benefit the underlying applicant(s) is/are applying;
- undertake and confirm that the underlying applicant(s) and the person for whose benefit the underlying applicant(s) is/are applying has/have not applied for or taken up, or indicated an interest for, or received or been placed or allocated (including conditionally and/or provisionally), and will not apply for or take up, or indicate an interest for, any International Offer Shares nor participate in the International Offering;
- understand that these declarations and representations will be relied upon by the Company, the Directors and the Joint Global Coordinators in deciding whether or not to allocate any of the Hong Kong Offer Shares in response to this application;
- authorise the Company to place the name(s) of the underlying applicant(s) on the register of members of the Company as the holder(s) of any Hong Kong Offer Shares to be allotted to them, and (subject to the terms and conditions set out in this Application Form) to send any share certificate(s) and/or any refund cheque(s) (where applicable) by ordinary post at that underlying applicant's own risk to the address stated on this Application Form in accordance with the procedures prescribed in this Application Form and in the Prospectus;
- instruct and authorise the Company and/or the Joint Global Coordinators (or their respective agents or nominees), as agents of the Company, to execute any documents on behalf of the underlying applicant(s) and to do on behalf of the underlying applicant(s) all things necessary to effect the registration of any Hong Kong Offer Shares allocated to the underlying applicant(s) in the name(s) of the underlying applicant(s) as required by the Constitution, and otherwise to give effect to the arrangements described in the Prospectus and this Application Form except where the underlying applicant has applied for 1,000,000 or more Hong Kong Offer Shares and that underlying applicant collects any Share certificate(s) in person in accordance with the procedures prescribed in this Application Form and in the Prospectus;
- request that any e-Refund payment instructions be dispatched to the application payment bank account where the applicants had paid the application monies from a single bank account;
- request that any refund cheque(s) be made payable to the underlying applicant(s) who had used multiple bank accounts to pay the application monies and to send any such refund cheque(s) by ordinary post at that underlying applicant's own risk to the address stated on the application in accordance with the procedures prescribed in this Application Form, the designated White Form eIPO website at www.eipo.com.hk and in the Prospectus;
- confirm that each underlying applicant has read the terms and conditions and application procedures set out in this Application Form, the designated White Form eIPO website at www.eipo.com.hk and in the Prospectus and agrees to be bound by them;
- represent, warrant and undertake that (a) the underlying applicant(s) and any persons for whose benefit the underlying applicant(s) is/are applying is/are not restricted by any laws of Hong Kong or elsewhere from making this application, paying any application monies for, or being allocated or taking up, any Hong Kong Offer Shares and the underlying applicant(s) and any persons for whose benefit the underlying applicant(s) is/are applying is/are outside the United States when completing and submitting this application and is/are a person described in paragraph (b)(3) of Rule 902 of Regulation S and the underlying applicant(s) and any persons for whose benefit the underlying applicant(s) is/are applying will acquire the Hong Kong Offer Shares in an offshore transaction (within the meaning of Regulation S); and (b) the allotment of or application for the Hong Kong Offer Shares to or by each underlying applicant or for whose benefit this application is made would not require the Company to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong;
- agree that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong; and
- agree that the Company and the Relevant Persons are entitled to rely on any warranty or representation made by us or the underlying applicants.

吾等確認，吾等已(i)遵守電子公開發售指引及通規、銀行/股票經紀遞交白表eIPO申請的運作程序以及與吾等就香港公開發售提供白表eIPO服務有關的所有適用法律法規、法定或其他，及(ii)細閱招股章程及本申請表格所載的條款及條件及申請手續，並同意受其約束。為代表與本申請有關的每一個相關申請人作出申請，吾等：

- 按照招股章程及本申請表格的條款及條件，並在招股章程大綱及細則的規限下，申請以下數目的香港發售股份；
- 隨附申請香港發售股份所需的全數付款(包括1.0%的經紀佣金、0.0027%的證監會交易費及0.005%的聯交所交易費)；
- 確認相關申請人已承諾及同意接納彼等根據本申請所申請的香港發售股份，或彼等根據本申請獲分配的任何較少數目香港發售股份；
- 聲明本申請乃由相關申請人以相關申請人或相關申請人代為申請的人士為受益人以白色或黃色申請表格或透過白表eIPO服務(www.eipo.com.hk)向香港結算或透過指定白表eIPO服務供應商發出電子認購指示所作出及擬作出的唯一申請；
- 承諾及確認相關申請人及相關申請人為其利益而提出申請的人士並無申請或接納或表示有意認購或收取或獲配任何股份(包括有條件及/或待定)，並將不會申請或接納或表示有意認購任何國際發售股份，亦不會參與國際發售；
- 明白 貴公司、董事及聯席全球協調人將依賴此等聲明及陳述決定是否就是項申請分配任何香港發售股份；
- 授權 貴公司將相關申請人的姓名/名稱列入 貴公司股東名冊內，作為任何將配發予相關申請人的香港發售股份的持有人，並(在符合本申請表格所載的條款及條件的情況下)根據本申請表格及招股章程所載程序按本申請表格上所示地址以普通郵遞方式寄發任何股票及/或任何退款支票(如適用)，郵誤風險概由該相關申請人承擔；
- 指示及授權 貴公司及/或聯席全球協調人(或彼等各自的代理或代名人)，作為 貴公司代理代表相關申請人簽發任何文件，並代表相關申請人進行一切必要事宜，以按照組織章程的規定，以相關申請人名義登記相關申請人獲分配的任何香港發售股份，並以其他方式令招股章程及本申請表格所述之安排生效，惟相關申請人已申請1,000,000股或以上香港發售股份及相關申請人根據本申請表格及招股章程所載程序親身領取任何股票的情況則除外；
- 要求將任何電子退款指示發送到申請人以單一銀行賬戶繳交申請股款的申請付款銀行賬戶內；
- 要求任何以多個銀行賬戶繳交申請股款的申請人的退款支票以相關申請人為抬頭人，並根據本申請表格、白表eIPO指定網站www.eipo.com.hk及招股章程所述程序將任何有關退款支票以普通郵遞方式寄發到申請所列的地址，郵誤風險概由相關申請人承擔；
- 確認各相關申請人已細閱本申請表格、白表eIPO指定網站www.eipo.com.hk及招股章程所載的條款、條件及申請手續，及同意受其約束；
- 聲明、保證及承諾(a)相關申請人及相關申請人為其利益提出申請的任何人士並不受香港或其他地方之任何適用法律限制提出本申請，支付任何申請股款或獲分配或接納任何香港發售股份及相關申請人及相關申請人為其利益提出申請的任何人士在填寫及提交申請時身處美國境外及屬S規例第902條第(b)(3)段所述的人士且相關申請人及相關申請人為其利益提出申請的任何人士會於離岸交易(定義見S規例)中認購香港發售股份；及(b)向各相關申請人或由各相關申請人或為其利益而提出本申請的人士公開發售或申請香港發售股份，不會引致 貴公司須從香港以外任何地區的任何法律或規例的任何規定(不論是具法律效力)；
- 同意本申請、對本申請的任何接納及據此訂立的合約，將受香港法例規管及按其詮釋；及
- 同意 貴公司及有關人士有權倚賴我們或相關申請人作出的任何保證或陳述。

Signature 簽名	Date 日期
Name of applicant 申請人姓名	Capacity 身份

2 We, on behalf of the underlying applicants, offer to purchase 吾等(代表相關申請人)提出認購	Total number of Shares 股份總數	Hong Kong Offer Shares on behalf of the underlying applicants whose details are contained in the read-only CD-ROM submitted with this Application Form. 代表相關申請人提供認購的香港發售股份(申請人的詳細資料包含於連同本申請表格遞交的唯讀光碟)。
---	--------------------------------	---

3 A total of 隨附合共	cheque(s) 支票	Cheque Number(s) 支票編號
are enclosed for a total sum of 總金額為	HK\$	Name of Bank 銀行名稱
	港元	

4 Please use BLOCK letters 請用正楷填寫	Name of White Form eIPO Service Provider 白表eIPO服務供應商名稱		White Form eIPO Service Provider ID 白表eIPO服務供應商編號	
Chinese Name 中文名稱	Name of contact person 聯絡人士姓名		Contact number 聯絡電話號碼	Fax number 傳真號碼
Address 地址	For Broker use 此欄供經紀填寫 Lodged by 申請由以下經紀遞交			
	Broker No. 經紀號碼			
	Broker's Chop 經紀印章			
	For Bank Use 此欄供銀行填寫			

GUIDELINES TO COMPLETING THIS APPLICATION FORM

References to boxes below are to the numbered boxes on this Application Form.

1 Sign and date the Application Form in Box 1. Only written signature will be accepted.

The name and the representative capacity of the signatory should also be stated. To apply for Hong Kong Offer Shares using this Application Form, you must be named in the list of **White Form eIPO Service Providers** who may provide **White Form eIPO** services in relation to the Hong Kong Public Offering, which was released by the SFC.

2 Put in Box 2 (in figures) the total number of Hong Kong Offer Shares for which you wish to apply on behalf of the underlying applicants.

Application details of the underlying applicants on whose behalf you are applying must be contained in one data file in read-only CD-ROM format submitted together with this Application Form.

3 Complete your payment details in Box 3.

You must state in this box the number of cheques you are enclosing together with this Application Form; and you must state on the reverse of each of those cheques (i) your **White Form eIPO Service Provider ID**; and (ii) the file number of the data file containing application details of the underlying applicant(s).

The dollar amount(s) stated in this box must be equal to the amount payable for the total number of Hong Kong Offer Shares applied for in Box 2. All cheque(s) and this Application Form together with a sealed envelope containing the CD-ROM, if any, must be placed in the envelope bearing your company chop.

For payments by cheque, the cheque must:

- be in Hong Kong dollars;
- not be post dated;
- be drawn on a Hong Kong dollar bank account in Hong Kong;
- show your (or your nominee's) account name;
- be made payable to "BANK OF CHINA (HONG KONG) NOMINEES LIMITED – KINTOR PHARMACEUTICAL PUBLIC OFFER";
- be crossed "Account Payee Only"; and
- be signed by the authorised signatories of the **White Form eIPO Services Provider**.

Your application may be rejected if any of these requirements is not met or if the cheque is dishonored on its first presentation.

It is your responsibility to ensure that details on the cheque(s) submitted correspond with the application details contained in the CD-ROM or data file submitted in respect of this application. The Company and the Joint Global Coordinators have full discretion to reject any applications in the case of discrepancies.

No receipt will be issued for sums paid on application.

4 Insert your details in Box 4 (using BLOCK letters).

You should write the name, **White Form eIPO Service Provider ID** and address of the **White Form eIPO Service Provider** in this box. You should also include the name and telephone number of the contact person at your place of business and where applicable, the Broker No. and Broker's Chop.

Personal Information Collection Statement

The main provisions of the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the "Ordinance") came into effect in Hong Kong on December 20, 1996. This Personal Information Collection Statement informs the applicant for and holder of the Shares of the policies and practices of the Company and the Hong Kong Share Registrar in relation to personal data and the Ordinance.

1. Reasons for the collection of your personal data

From time to time it is necessary for applicants for securities or registered holders of securities to supply their latest correct personal data to the Company and/or the Hong Kong Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the Hong Kong Share Registrar.

Failure to supply the requested data may result in your application for securities being rejected or in delay or inability of the Company and/or the Hong Kong Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfer of the Hong Kong Offer Shares which you have successfully applied for and/or the despatch of share certificate(s), and/or the despatch of e-Refund payment instructions, and/or the despatch of refund cheque(s) to which you are entitled.

It is important that the applicants and the holders of securities inform the Company and the Hong Kong Share Registrar immediately of any inaccuracies in the personal data supplied.

2. Purposes

The personal data of the applicants and holders of securities may be used, held and/or stored (by whatever means) for the following purposes:

- processing of your application and refund cheque, where applicable, and verification of compliance with the terms and application procedures set out in this Application Form and the Prospectus and announcing results of allocations of the Hong Kong Offer Shares;
- compliance with all applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of holders of securities including, where applicable, in the name of HKSCC Nominees;
- maintaining or updating the register of securities' holders of the Company;
- conducting or assisting to conduct signature verifications, any other verification or exchange of information;
- establishing benefit entitlements of securities' holders of the Company, such as dividends, rights issues, bonus issues, etc;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and securities' holders profiles;
- making disclosures as required by laws, rules or regulations;
- disclosing identities of successful applicants by way of press announcement(s) or otherwise;
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable the Company and the Hong Kong Share Registrar to discharge their obligations to holders of securities and/or regulators and any other purpose to which the holders of securities may from time to time agree.

3. Transfer of personal data

Personal data held by the Company and the Hong Kong Share Registrar relating to the applicants and the holders of securities will be kept confidential but the Company and its Hong Kong Share Registrar may, to the extent necessary for achieving the above purposes or any of them, make such enquiries as they consider necessary to confirm the accuracy of the personal data and in particular, they may disclose, obtain, transfer (whether within or outside Hong Kong) the personal data of the applicants and the holders of securities to, from or with any and all of the following persons and entities:

- the Company or its appointed agents such as financial advisers, the receiving bankers and overseas Principal Share Registrar;
- where applicants for securities request deposit into CCASS, to HKSCC and HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company and/or the Hong Kong Share Registrar in connection with the operation of their respective businesses;
- any regulatory or governmental bodies (including the Stock Exchange and the SFC); and
- any other persons or institutions with which the holders of securities have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers, etc.

4. Retention of personal data

The Company and the Hong Kong Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfill the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed on dealt with in accordance with the Ordinance.

5. Access and correction of personal data

The Ordinance provides the applicants and the holders of securities with rights to ascertain whether the Company and/or the Hong Kong Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. In accordance with the Ordinance, the Company and the Hong Kong Share Registrar have the right to charge a reasonable fee for the processing of any data access request. All requests for access to data or correction of data or for information regarding policies and practices and the kinds of data held should be addressed to the Company for the attention of the Company secretary or (as the case may be) the Hong Kong Share Registrar for the attention of the Privacy Compliance Officer for the purposes of the Ordinance.

By signing an Application Form, you agree to all of the above.

填寫本申請表格的指引

下文各欄提述的號碼乃本申請表格中各欄的編號。

1 在申請表格欄1簽署及填上日期。只接受親筆簽名。

亦必須註明簽署人的姓名／名稱及代表身份。如欲使用本申請表格申請香港發售股份，閣下必須為名列於證監會公佈的**白表eIPO**服務供應商名單內可以就香港公開發售提供**白表eIPO**服務的供應商。

2 在欄2填上閣下欲代表相關申請人申請的香港發售股份總數（以數字填寫）。

閣下代表其作出申請的相關申請人的申請詳細資料，必須載入連同本申請表格遞交的唯讀光碟格式的一個資料檔案內。

3 在欄3填上閣下付款的詳細資料。

閣下必須在本欄註明閣下連同本申請表格隨附的支票數目；及閣下必須在每張支票的背面註明(i) 閣下的**白表eIPO**服務供應商編號；及(ii)載有相關申請人的申請詳細資料的資料檔案的檔案編號。

本欄所註明的金額必須與欄2所申請的香港發售股份總數應付的金額相同。所有支票及本申請表格連同裝有唯讀光碟的密封信封（如有）必須放進蓋上閣下公司印章的信封內。

如以支票繳付股款，該支票必須：

- 為港元支票；
- 不得為期票；
- 由在香港開設的港元銀行賬戶付款；
- 顯示閣下（或閣下代名人）的賬戶名稱；
- 註明抬頭人為「中國銀行（香港）代理有限公司 – KINTOR PHARMACEUTICAL 公開發售」；
- 以「只准入抬頭人賬戶」劃線方式開出；及
- 由**白表eIPO**服務供應商的授權簽署人簽署。

倘未能符合任何此等規定或倘支票首次過戶不獲兌現，閣下的申請可能會遭拒絕受理。

閣下有責任確保所遞交的支票上的詳細資料與就本申請遞交的唯讀光碟或資料檔案所載的申請詳細資料相同。倘出現差異，本公司及聯席全球協調人有絕對酌情權拒絕接受任何申請。

申請時繳付的金額將不會獲發收據。

4 在欄4填上閣下的詳細資料（用正楷填寫）。

閣下必須在本欄填上**白表eIPO**服務供應商的名稱、**白表eIPO**服務供應商編號及地址。閣下亦必須填寫閣下營業地點的聯絡人士的姓名及電話號碼及（如適用）經紀號碼及經紀印章。

個人資料收集聲明

香港法例第486章《個人資料（私隱）條例》（「**條例**」）中的主要條文於1996年12月20日在香港生效。此份個人資料收集聲明是向股份申請人及持有人說明本公司及香港證券登記處有關個人資料及《條例》的政策及慣例。

1. 收集閣下個人資料之原因

證券申請人或證券登記持有人申請證券或將證券轉往其名下，或將名下證券轉讓予他人，或要求香港證券登記處提供服務時，須不時向本公司及／或香港證券登記處提供其最新的正確個人資料。

若未能提供所需資料，可能會導致閣下的證券申請遭拒絕受理或本公司及／或香港證券登記處延遲或不能使證券過戶生效或提供其他服務，亦可能妨礙或延誤閣下成功申請的香港發售股份的登記或過戶及／或妨礙或延誤寄發股票，及／或發送電子退款指示，及／或寄發閣下應得的退款支票。

證券申請人及持有人提供的個人資料如有任何不確，必須即時知會本公司及香港證券登記處。

2. 資料用途

證券申請人及持有人的個人資料可以任何方式被採用、持有及／或保存，以作下列用途：

- 處理閣下的申請及退款支票（如適用）、核實是否遵守本申請表格及招股章程所載條款及申請手續以及公佈香港發售股份的分配結果；
- 遵守香港及其他地區的所有適用法律及法規；
- 以證券持有人（包括香港結算代理人（如適用））的名義登記新發行證券或轉讓或受讓證券；
- 存置或更新本公司證券持有人的名冊；
- 進行或協助進行簽名核對、任何其他核對或交換資料；
- 確定本公司證券持有人的受益權利，例如股息、供股和紅股等；
- 分發本公司及其附屬公司的通訊資料；
- 編製統計數據和證券持有人資料；
- 遵照法例、規則或規例的要求作出披露；
- 透過報章公佈或其他方式披露成功申請人士的身份；
- 披露有關資料以便就權益索償；及
- 與上述有關的任何其他附帶或相關目的及／或使本公司及香港證券登記處能履行對證券持有人及／或監管機構承擔的責任及證券持有人可能不時同意的任何其他目的。

3. 轉交個人資料

本公司及香港證券登記處會將其持有證券申請人及持有人的個人資料保密，但本公司及其香港證券登記處可能會就上述目的或上述任何目的作出彼等認為必要的查詢以確認個人資料的準確性，尤其可能會向下列任何及所有人士及實體披露、索取或轉交證券申請人及持有人的個人資料（不論在香港或外地）：

- 本公司或其委任的代理，例如財務顧問、收款銀行及海外證券登記總處；
- 倘證券申請人要求將證券存入中央結算系統，向香港結算及香港結算代理人，而彼等將為運作中央結算系統而使用個人資料；
- 任何向本公司及／或香港證券登記處提供與其各自業務運作有關的行政、電訊、電腦、付款或其他服務的代理、承包商或第三方服務供應商；
- 任何監管或政府機關（包括聯交所及證監會）；及
- 與證券持有人有或擬有業務往來的任何其他人士或機構，例如銀行、律師、會計師或股票經紀等。

4. 個人資料的保留

本公司及香港證券登記處將按收集個人資料所需的用途保留證券申請人及持有人的個人資料。無需保留的個人資料將會根據《條例》銷毀或處理。

5. 查閱及更正個人資料

《條例》賦予證券申請人及持有人權利以確定本公司及／或香港證券登記處是否持有其個人資料、索取有關資料的副本及更正任何不正確的資料。根據《條例》規定，本公司及香港證券登記處有權就處理任何查閱資料的要求收取合理費用。根據《條例》，所有關於查閱資料或更正資料或索取關於政策及慣例及所持資料類別的資料的要求，應向本公司的公司秘書或（視情況而定）由香港證券登記處向私隱事務主任提出。

閣下簽署申請表格，即表示同意上述各項。

DELIVERY OF THIS APPLICATION FORM

This completed Application Form, together with the appropriate cheque(s) together with a sealed envelope containing the CD-ROM, must be submitted to the following receiving bank by 4:00 p.m. on Friday, May 15, 2020:

Bank of China (Hong Kong) Limited
6/F, Bank of China Centre
11 Hoi Fai Road
West Kowloon

遞交本申請表格

經填妥的本申請表格，連同適用支票及裝有相關唯讀光碟的密封信封，必須於2020年5月15日（星期五）下午四時正之前，送達下列收款銀行：

中國銀行（香港）有限公司
西九龍
海輝道11號
中銀中心6樓